目的 探討摩羅丹聯(lián)合鹽酸伊托必利分散片治療慢性萎縮性胃炎的臨床療效。方法 選取2019年3月—2022年1月在安徽醫(yī)科大學(xué)第四附屬醫(yī)院就診的75例慢性萎縮性胃炎患者，按隨機(jī)數(shù)字表法分為對(duì)照組（37例）和治療組（38例）。對(duì)照組飯前口服伊托必利分散片，1片/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服摩羅丹，1丸/次，3次/d。兩組患者連續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組胃脘主觀疼痛程度、主要組織學(xué)狀態(tài)（慢性炎癥、腸化、萎縮）、血清中的轉(zhuǎn)化生長(zhǎng)因子-α（TGF-α）、表皮生長(zhǎng)因子（EGF）、胃泌素17水平。結(jié)果 治療后，治療組的總有效率94.74%，對(duì)照組的總有效率為78.38%，組間比較有顯著差異（P＜0.05）。治療后，兩組的視覺(jué)模擬評(píng)分法（VAS）評(píng)分均顯著降低（P＜0.05），治療組VAS評(píng)分明顯低于對(duì)照組（P＜0.05）。治療后，兩組的慢性炎癥、腸化、萎縮均顯著減輕（P＜0.05），治療組慢性炎癥、腸化、萎縮較對(duì)照組減輕更明顯（P＜0.05）。治療后，兩組的血清TGF-α、EGF水平低于治療前，胃泌素17水平明顯高于治療前（P＜0.05）；治療組的血清TGF-α、EGF水平比對(duì)照組低，胃泌素17水平比對(duì)照組高（P＜0.05）。結(jié)論 摩羅丹聯(lián)合鹽酸伊托必利分散片治療慢性萎縮性胃炎的療效確切，能降低疼痛程度和炎癥反應(yīng)，減輕腸化、萎縮癥狀，且安全性良好。

Objective To investigate the clinical effect of Moluodan combined with Itopride Hydrochloride Dispersible Tablets in treatment of chronic atrophic gastritis. Methods Patients (75 cases) with chronic atrophic gastritis in the Fourth Affiliated Hospital of Anhui Medical University from January 2019 to February 2022 were randomly divided into the control group (37 cases) and the treatment group (38 cases). Patients in the control group were po administered with Itopride Hydrochloride Dispersible Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Moluodan on the basis of the control group, 1 pill/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the pain degree of gastral cavity, the main histological status (chronic inflammation, intestinal metaplasia, and atrophy), the serum levels of TGF-α, EGF, and gastrin 17 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.74%, that of the control group was 78.38%, and there was significant difference between two groups (P < 0.05). After treatment, the VAS score of two groups were significantly decreased (P < 0.05), and the VAS score of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the chronic inflammation, intestinal metaplasia, and atrophy in two groups were significantly decreased (P < 0.05), and the chronic inflammation, intestinal metaplasia and atrophy in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum levels of TGF-α and EGF in two groups were lower than those before treatment, but the serum level of gastrin 17 in two groups was significantly higher than that before treatment (P < 0.05). The serum levels of TGF-α and EGF in the treatment group were lower than those in the control group, butd the serum level of gastrin 17 in the treatment group was higher than that in the control group (P < 0.05).Conclusion Moluodan combined with Itopride Hydrochloride Dispersible Tablets is effective in treatment of chronic atrophic gastritis, which can reduce the degree of pain, reduce the inflammatory reaction, and relieve the symptoms of intestinal metaplasia and atrophy, with good safety.

R975

安徽醫(yī)科大學(xué)高等學(xué)校省級(jí)質(zhì)量工程項(xiàng)目(2020 jyxm0907)